Volume 385, Issue 9977, Pages (April 2015)

Slides:

Advertisements

Similar presentations

Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial,

Advertisements

Volume 387, Issue 10037, Pages (June 2016)

Volume 350, Issue 9071, Pages (July 1997)

Volume 355, Issue 9206, Pages (March 2000)

Volume 357, Issue 9273, Pages (June 2001)

Volume 367, Issue 9517, Pages (April 2006)

Volume 375, Issue 9729, Pages (May 2010)

Volume 357, Issue 9257, Pages (March 2001)

Volume 370, Issue 9601, Pages (November 2007)

Volume 359, Issue 9322, Pages (June 2002)

Volume 17, Issue 12, Pages (December 2016)

Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled,

Volume 385, Issue 9984, Pages (June 2015)

Volume 378, Issue 9785, Pages (July 2011)

Volume 376, Issue 9734, Pages (July 2010)

Association of CD4+ T-lymphocyte counts and new thymic emigrants in HIV-infected children during successful highly active antiretroviral therapy Akihiko.

Volume 372, Issue 9633, Pages (July 2008)

Volume 391, Issue 10120, Pages (February 2018)

Volume 389, Issue 10069, Pages (February 2017)

Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double-blind, randomised controlled trial

Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China:

Volume 371, Issue 9611, Pages (February 2008)

Volume 376, Issue 9734, Pages (July 2010)

Volume 372, Issue 9633, Pages (July 2008)

Volume 381, Issue 9871, Pages (March 2013)

Ebola virus epidemic in war-torn eastern DR Congo

Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled,

Characteristics and survival of patients with Ebola virus infection, malaria, or both in Sierra Leone: a retrospective cohort study Matthew Waxman, MD,

Volume 385, Issue 9966, Pages (January 2015)

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials David Moher, MSc, Kenneth F Schulz,

Stem Cell Therapies in Clinical Trials: Progress and Challenges

Volume 392, Issue 10147, Pages (August 2018)

Long-term sequelae after Ebola virus disease in Bundibugyo, Uganda: a retrospective cohort study Dr Danielle V Clark, PhD, Hannah Kibuuka, MD, Monica.

Volume 2, Issue 6, Pages (June 2015)

Volume 9, Issue 10, Pages (October 2008)

Misoprostol for small bowel ulcers in patients with obscure bleeding taking aspirin and non-steroidal anti-inflammatory drugs (MASTERS): a randomised,

Safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled.

Volume 375, Issue 9732, Pages (June 2010)

Volume 384, Issue 9944, Pages (August 2014)

Volume 378, Issue 9785, Pages (July 2011)

Volume 385, Issue 9984, Pages (June 2015)

Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double- blind, parallel-group, placebo-controlled trial Dr Andrew R Goudie,

Safety, pharmacokinetics, and immunogenicity of a co-formulated cocktail of three human monoclonal antibodies targeting Ebola virus glycoprotein in healthy.

Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled,

Volume 5, Issue 7, Pages e366-e378 (July 2018)

Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre,

Volume 386, Issue 10011, Pages (December 2015)

Volume 388, Issue 10058, Pages (November 2016)

Reproductive health for refugees

Volume 388, Issue 10056, Pages (October 2016)

The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial

A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled,

Volume 393, Issue 10174, Pages (March 2019)

Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double-blind, randomised controlled trial

Volume 15, Issue 13, Pages (December 2014)

Primary prophylaxis of cryptococcal disease with fluconazole in HIV-positive Ugandan adults: a double-blind, randomised, placebo-controlled trial Dr.

Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial,

Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled,

Volume 367, Issue 9518, Pages (April 2006)

Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding,

Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled,

Volume 372, Issue 9632, Pages (July 2008)

Effect of a behaviour change intervention on the quality of peri-urban sanitation in Lusaka, Zambia: a randomised controlled trial James B Tidwell, PhD,

Volume 376, Issue 9737, Pages (July 2010)

Volume 383, Issue 9930, Pages (May 2014)

Clinic attendance and disengagement of young adults with type 1 diabetes after transition of care from paediatric to adult services (TrACeD): a randomised,

Volume 371, Issue 9611, Pages (February 2008)

Volume 18, Issue 6, Pages (June 2019)

Volume 394, Issue 10193, Pages (July 2019)

Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind,

Presentation transcript:

Volume 385, Issue 9977, Pages 1545-1554 (April 2015) Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial Hannah Kibuuka, MMed, Nina M Berkowitz, MPH, Monica Millard, MPH, Mary E Enama, MA, Allan Tindikahwa, MPH, Arthur B Sekiziyivu, MSc, Pamela Costner, BSN, Sandra Sitar, MS, Deline Glover, BS, Zonghui Hu, PhD, Gyan Joshi, MPH, Daphne Stanley, MS, Meghan Kunchai, MPH, Leigh Anne Eller, PhD, Robert T Bailer, PhD, Richard A Koup, MD, Gary J Nabel, MD, John R Mascola, MD, Nancy J Sullivan, PhD, Barney S Graham, MD, Mario Roederer, PhD, Nelson L Michael, MD, Merlin L Robb, MD, Dr Julie E Ledgerwood, DO The Lancet Volume 385, Issue 9977, Pages 1545-1554 (April 2015) DOI: 10.1016/S0140-6736(14)62385-0 Copyright © 2015 Elsevier Ltd Terms and Conditions

Figure 1 Trial profile The Lancet 2015 385, 1545-1554DOI: (10.1016/S0140-6736(14)62385-0) Copyright © 2015 Elsevier Ltd Terms and Conditions

Figure 2 CD4 T-cell responses to all antigens assessed by intracellular cytokine staining (A) Median CD4 responses (error bars show IQRs). Responses reached near maximum levels at week 12 (4 weeks after the third vaccination) and persisted for about 1 year. Week 8 is the time of the third vaccination, so the response at that timepoint is after two injections. Only significant p values (p<0·05) are shown. (B) Median CD4 responses by antigen at 4 weeks after the third vaccination. Responses were not cross-reactive between EBO and MAR vaccine groups. Only significant p values (p<0·05) are shown. (C) Qualitative profiles of antigen-specific polyfunctional memory T-cell responses are shown by cytokine at week 12. Data are shown if more than five individuals can be averaged and are only shown for positive responders (n is the number of positive responders). The Lancet 2015 385, 1545-1554DOI: (10.1016/S0140-6736(14)62385-0) Copyright © 2015 Elsevier Ltd Terms and Conditions